DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies

Sessions to Highlight Patient Voices, Alzheimer’s, Big Data

DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies

DIAEric Rosen, 215-290-9153

The , to be held June 23–27 at the Boston Convention & Exhibition Center, will feature 22 tracks and more than 250 educational offerings, including sessions addressing urgent issues surrounding patient advocacy, big data and Alzheimer’s. These sessions, along with a large number of panels, forums and networking opportunities, aim to foster collaboration and drive conversation between patients and key industry and regulatory professionals to advance the development and regulation of safe and effective medical products.

Sessions include:

Susan Dentzer, editor-in-chief of the leading peer-reviewed medical journal Health Affairs, will chair this discussion about how data are being used to support safety and efficiency, about how data affect the payer landscape, and to share best practices. Dentzer will be joined by keynote speaker Michael Rosenblatt, chief medical officer of Merck & Co., along with an esteemed panel of experts representing the pharmaceutical industry, regulatory affairs, clinical research and patient perspectives.

Avariety of sessions will focus on advancing care in Alzheimer’s disease, bringing together representatives from the patient advocacy and industry communities.

A panel of current fellows and alumni from the DIA Patient Advocate Fellowship Program will share inspiring stories of advancing patient engagement through their organizations. Patients and advocates will discuss how organizations can take vital steps to improve development of treatment, such as setting up registries to collect patient data, educating patients on diseases, working hand in hand with clinicians and researchers, identifying and boosting attendance for clinical trials and navigating the pharmaceutical industry and regulation to advance the development of treatment for diseases, especially in cases in which no treatment yet exists.

For more information, visit .

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., with offices in Basel, Switzerland; Tokyo; Mumbai, India; and Beijing.

Suggested Articles

Blue Shield of California is teaming up with Accolade to offer self-insured employers a personalized way to connect with members about their benefits.

After spending the past three years leading technology strategy at HHS, Ed Simcox left to help grow a startup focused on precision medicine.

Apple is pushing deeper into health research with a new study leveraging the Apple Watch and smartphone apps.